Compare S&P Global Inc (SPGI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs TransMedics Group Inc — how do they compare? S&P Global Inc trades at $405.66 (market cap $118.72B), while TransMedics Group Inc trades at $77.75 (market cap $2.74B). The key difference: S&P Global Inc is far larger — about 43.3× TransMedics Group Inc's market cap, and S&P Global Inc pays a 0.96% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold S&P Global Inc for 123 Days and TransMedics Group Inc for 24 Days on average.
| SPGI | TMDX | |
|---|---|---|
Market Cap | $118.72B | $2.74B |
Volume | 1,647,917 | 949,331 |
Sector | Financials | Health |
52-Week High | $517.92 | $150.42 |
52-Week Low | $370.42 | $61.99 |
Typical Hold Time | 123 Days | 24 Days |
Enterprise Value | $130.21B | $3.13B |
Dividend Yield | 0.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $406.06, up 2.75% today, with strong analyst support (85.7% buy ratings) and a consensus price target of $509.50. The stock shows robust fundamentals, including 30.54% net income margin and consistent revenue growth, though technical indicators signal near-term bearish pressure. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives, positioning the company for future revenue streams.
Outlook remains positive due to high profitability, strategic acquisitions, and dominant market position, but risks include competitive pressures and macroeconomic sensitivity. The stock offers upside based on analyst targets, supported by stable cash flows and dividend payments, making it a compelling hold for long-term investors despite technical headwinds.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
